NCT01862003已完成2 期
AZD8931, an Inhibitor of EGFR, ERBB2 and ERBB3 Signalling, in Combination With FOLFIRI: a Phase I/II Study to Determine the Importance of Schedule and Activity in Colorectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 4
- 主要终点
- Best overall response
研究概览
简要总结
Recruitment to phase I of the PANTHER trial is complete.
Phase II, is to evaluate the best overall response rate for AZD8931 + FOLFIRI treatment.
详细描述
PANTHER is a registered phase I/phase II trial in patients with recurrent or metastatic colorectal cancer.
The phase II part of the study will be a single arm trial. Patients will receive AZD8931 (an EGFR/ERBB inhibitor) in combination with FOLinic acid, Fluorouracil and IRInotecan (FOLFIRI), Treatment will be given in two-weekly cycles. Phase II's primary objective is to evaluate the Best overall response
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histopathological/cytological diagnosis of non-resectable, recurrent or metastatic colorectal cancer
- •Tumour with wild-type RAS
- •Measurable disease evaluated by RECIST criteria v1.1
- •WHO performance status 0 or 1
- •Estimated life expectancy > 3 months
- •Adequate haematological function:
- •Haemoglobin ≥100 g/L
- •Absolute neutrophil count ≥1.5 x 10^9/L
- •Platelet count ≥100 x 10^9/L
- •Adequate liver function:
- •Total bilirubin ≤1.5 x upper limit of normal (ULN) (except for patients with known documented cases of Gilbert's syndrome)
- •ALT, AST & ALP ≤2.5 x ULN in the absence of noted liver metastases
- •ALT, AST & ALP ≤5 x ULN in the presence of liver metastases
- •Adequate renal function:
- •Serum creatinine ≤1.5 x ULN
- •Calculated creatinine clearance ≥30 mL/min
- •Adequate biliary drainage (patients with stents are eligible)
- •Adequate venous access for collection of exploratory biological samples
- •Women of child-bearing potential must have a negative pregnancy test prior to study entry. Female patients and male patients with partners of child-bearing potential must agree to use an adequate contraception method, which must be continued for 6 months after completion of chemotherapy
- •Must be able to swallow AZD8931 tablets
- •Capable of giving written informed consent
- •The following prior therapy is allowed:
- •Surgery - patients may have undergone a non-curative operation or palliative bypass surgery only. Patients who have previously undergone curative surgery must have evidence of non-resectable disease relapse
- •Radiotherapy - for localised disease
- •Prior adjuvant chemotherapy - provided this was completed at least 6 months before trial entry
排除标准
- •Patients undergoing treatment with curative intent
- •Any prior treatment with agents targeting the ERBB pathway
- •Treatment with experimental drugs within 30 days or 5 half-lives of first dose of AZD8931
- •Previous palliative chemotherapy
- •Prior treatment with anthracyclines or mitoxantrone
- •Current disease or condition known to interfere with absorption, distribution, metabolism or excretion of drugs (including refractory nausea and vomiting, chronic gastrointestinal disease (e.g. inflammatory bowel disease), or significant bowel resection)
- •History of prior malignancy that will interfere with the response evaluation (exceptions listed in protocol)
- •Evidence of severe/uncontrolled systemic diseases or laboratory finding that makes it undesirable for the patient to participate in the trial
- •Evidence of active uncontrolled infection
- •Patients with clinically significant ascites and/or effusions
- •Regular use of anti-diarrhoeal
- •Pregnant or lactating women
- •Cardiac conditions (as detailed in the trial protocol)
- •Any psychiatric or other disorder (e.g. brain metastases) likely to impact the ability to give informed consent
- •Eye conditions (as detailed in the trial protocol)
- •Patients with chronic skin conditions e.g. acne rosacea, psoriasis, severe atopic eczema
- •Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
- •History or repeated unexplained episodes of syncope/dizziness
- •Known hypersensitivity to AZD8931, its excipients, or drugs in its class
- •The use of drugs/substances known to inhibit or induce CYP3A4 or CYP2D6, or those known to prolong QT interval, which cannot be discontinued for the duration of trial treatment
- •Patients with hereditary fructose intolerance
研究组 & 干预措施
Arm 1
Experimental
AZD8931 160 mg bd, on days 1-4, + FOLFIRI in a 2 weekly schedule
干预措施: AZD8931 (Drug)
Arm 1
Experimental
AZD8931 160 mg bd, on days 1-4, + FOLFIRI in a 2 weekly schedule
干预措施: Irinotecan (Drug)
Arm 1
Experimental
AZD8931 160 mg bd, on days 1-4, + FOLFIRI in a 2 weekly schedule
干预措施: Folinic Acid (Drug)
Arm 1
Experimental
AZD8931 160 mg bd, on days 1-4, + FOLFIRI in a 2 weekly schedule
干预措施: Fluorouracil (Drug)
结局指标
主要结局
Best overall response
时间窗: From registration to date of documented best response, assessed up to 36 months
Best overall response will be assessed according to RECIST v1.1.
次要结局
- To evaluate the efficacy of AZD8931 plus FOLFIRI(Baseline to 12 weeks post treatment start)
- Overall Survival(From date of registration/ randomisation until date of death or date of last follow-up assessment (up to 3 years from date of registration/ randomisation))
- Occurrence and Severity of Adverse Events(From date of registration/ randomisation until 30 days after completion of trial treatment (AZD8931 and FOLFIRI))
- Progression Free Survival(From date of randomisation to date of documented disease progression or death from any cause, whichever comes first, assessed up to 3 years from date of registration/ randomisation)
研究者
研究点 (4)
Loading locations...
相似试验
Unknown
2 期
Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLCLung Cancer, Non-small CellNCT02824952Shaare Zedek Medical Center40
已完成
2 期
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)de Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic SyndromesUntreated Adult Acute Myeloid LeukemiaNCT00475150National Cancer Institute (NCI)39
已完成
1 期
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaNCT00662506National Cancer Institute (NCI)46
招募中
2 期
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET TrialAdvanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmNCT05327010National Cancer Institute (NCI)88
招募中
1 期
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsER+ HER2- Advanced Breast CancerHigh-grade Serous Ovarian Cancer (HGSOC)NCT06188520AstraZeneca564